Literature DB >> 25790088

miR-125a--does the difference lie in the isoform?

Lihi Ninio-Many1, Ruth Shalgi, Irit Ben-Aharon.   

Abstract

Entities:  

Year:  2015        PMID： 25790088      PMCID： PMC4614516          DOI： 10.1080/15384101.2015.1010961

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  5 in total

1.  Prognostic role of microRNA polymorphisms in patients with advanced esophageal squamous cell carcinoma receiving platinum-based chemotherapy.

Authors:  Chaohui Wu; Minjie Li; Chao Hu; Hongbing Duan
Journal:  Cancer Chemother Pharmacol       Date:  2013-11-28       Impact factor: 3.333

2.  microRNA-125a-3p reduces cell proliferation and migration by targeting Fyn.

Authors:  Lihi Ninio-Many; Hadas Grossman; Noam Shomron; Dana Chuderland; Ruth Shalgi
Journal:  J Cell Sci       Date:  2013-04-19       Impact factor: 5.285

3.  Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells.

Authors:  Lili Jiang; Qin Huang; Siyang Zhang; Qingfu Zhang; Jihong Chang; Xueshan Qiu; Enhua Wang
Journal:  BMC Cancer       Date:  2010-06-22       Impact factor: 4.430

4.  MicroRNA miR-125a-3p modulates molecular pathway of motility and migration in prostate cancer cells.

Authors:  Irit Ben-Aharon; Ruth Shalgi; Lihi Ninio-Many; Hadas Grossman; Mattan Levi; Sofia Zilber; Ilan Tsarfaty; Noam Shomron; Anna Tuvar; Dana Chuderland; Salomon M Stemmer
Journal:  Oncoscience       Date:  2014-04-30

5.  rs12976445 variant in the pri-miR-125a correlates with a lower level of hsa-miR-125a and ERBB2 overexpression in breast cancer patients.

Authors:  Tomasz P Lehmann; Konstanty Korski; Mathew Ibbs; Piotr Zawierucha; Sylwia Grodecka-Gazdecka; Paweł P Jagodziński
Journal:  Oncol Lett       Date:  2012-11-22       Impact factor: 2.967
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.